Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

The article compares Abbott Laboratories and UnitedHealth Group as healthcare investment options. Abbott, with $44.3B in revenue and a conservative 0.3x debt-to-equity ratio, focuses on medical devices, diagnostics, and pharmaceuticals, with planned growth from the Exact Sciences acquisition and a nutrition business spin-off. UnitedHealth, with $447.6B in revenue but higher leverage at 0.8x debt-to-equity, dominates insurance and healthcare services but faces government policy risks and reputational challenges. The author recommends Abbott for its innovation focus and lower exposure to healthcare cost-control initiatives.